First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis

Glatt Sophie; Helmer Eric; Haier Birgit; Strimenopoulou Foteini; Price Graham; Vajjah Pavan; Harari Olivier A.; Lambert John; Shaw Stevan

首页> 外文期刊>British Journal of Clinical Pharmacology >First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis

【24h】

First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis

机译：Bimekizumab，人源化单克隆抗体和IL-17a和IL-17F的选择性双抑制剂的第一载于人类随机研究，在轻度牛皮癣中

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

AIMS

机译：目的

著录项

来源
《British Journal of Clinical Pharmacology》 |2017年第5期|共11页
作者
Glatt Sophie; Helmer Eric; Haier Birgit; Strimenopoulou Foteini; Price Graham; Vajjah Pavan; Harari Olivier A.; Lambert John; Shaw Stevan;
展开▼
作者单位

UCB Pharma Ltd 208 Bath Rd Slough SL1 3WE Berks England;

UCB Pharma Ltd 208 Bath Rd Slough SL1 3WE Berks England;

UCB Pharma Monheim Germany;

UCB Pharma Ltd 208 Bath Rd Slough SL1 3WE Berks England;

UCB Pharma Ltd 208 Bath Rd Slough SL1 3WE Berks England;

UCB Pharma Ltd 208 Bath Rd Slough SL1 3WE Berks England;

UCB Pharma Ltd 208 Bath Rd Slough SL1 3WE Berks England;

PAREXEL Int Uxbridge Middx England;

UCB Pharma Ltd 208 Bath Rd Slough SL1 3WE Berks England;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词
anti-IL17A; anti-IL17F; bimekizumab; interleukin-17; psoriasis; UCB4940;

机译：抗IL17A;抗IL17F;Bimekizumab;白细胞介素-17;牛皮癣;UCB4940;

相似文献

外文文献
中文文献
专利

1. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis [J] . Glatt Sophie, Helmer Eric, Haier Birgit, British Journal of Clinical Pharmacology . 2017,第5期

机译：Bimekizumab，人源化单克隆抗体和IL-17a和IL-17F的选择性双抑制剂的第一载于人类随机研究，在轻度牛皮癣中
2. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis [J] . Glatt Sophie, Helmer Eric, Haier Birgit, British Journal of Clinical Pharmacology . 2017,第5期

机译：Bimekizumab，人源化单克隆抗体和IL-17a和IL-17F的选择性双抑制剂的第一载于人类随机研究，在轻度牛皮癣中
3. First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis [J] . Sophie Glatt, Eric Helmer, Birgit Haier, British journal of clinical pharmacology . 2017,第5期

机译：人源化单克隆抗体和IL-17A和IL-17F选择性双重抑制剂bimekizumab在轻度牛皮癣中的首次人类随机研究
4. Deglycosylation Study of Murine IgG1, IgG2a, IgG2b, and Humanized IgG1 Monoclonal Antibodies [C] . Megan Ellis, John Lambert, Alexandru C. Lazar American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2011

机译：鼠IgG1，IgG2a，IgG2b和人源化IgG1单克隆抗体的脱糖基化研究
5. Generation of Highly Selective Monoclonal Antibodies Inhibiting Tumorigenic Proteases [D] . Nam, Dong Hyun 2015

机译：抑制致瘤蛋白酶的高选择性单克隆抗体的产生
6. First‐in‐human randomized study of bimekizumab a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F in mild psoriasis [O] . Sophie Glatt, Eric Helmer, Birgit Haier, 2017

机译：人源化单克隆抗体和IL-17A和IL-17F选择性双重抑制剂bimekizumab在轻度牛皮癣中的首次人类随机研究
7. OP0108 DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSA: OVERALL AND TNF-INHIBITOR-NAÏVE POPULATION RESULTS FROM A 48-WEEK PHASE 2B RANDOMISED STUDY [O] . Christopher T. Ritchlin, Arthur Kavanaugh, Joseph F. Merola, 2019

机译：op0108在活性PSA患者中与Bimekizumab的OP0108和IL-17F的双重中和：总体和TNF抑制剂 - 幼稚群体来自48周的2B型随机研究
8. Production of Humanized Monoclonal Antibodies against Bacillus Anthracis and Yersenia Pestis for the Urgent Prophalaxis and Therapy of Exposed Individuals [R] . Robinson, D. M. 2011

机译：针对炭疽杆菌和耶尔森氏菌的人源化单克隆抗体的生产，用于紧急预防和暴露个体的治疗

First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅